While omalizumab has shown promise in facilitating desensitization in IgE-mediated food allergies, such as in the MacGinnitie et al. study [10], where patients with peanut allergies maintained high levels of tolerance after discontinuing omalizumab, this outcome does not appear to extend to WDEIA. Here, IGHE is linked to peanut allergic reaction.